Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: Clinical and instrumental evaluation

Journal of Cosmetic Dermatology

Volumn 7, Issue 1, 2008, Pages 8-14

  Berardesca, Enzo ^a   Cameli, Norma ^a   Cavallotti, Claudia ^a   Levy, Jean Luc ^b   Piérard, Gérald E ^c   De Paoli Ambrosi, Gianfranco ^d  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b Scientifically Park of Luminy   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Worldwide Health Care Products ^*  (Italy)

Author keywords

Acne rosacea; Erythema; Telangiectases

Indexed keywords

DIMETHYL SULFONE; PLACEBO; SILYMARIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG RESPONSE; ELECTRIC CAPACITANCE; ERYTHEMA; FEMALE; HUMAN; HYDRATION; MALE; OUTCOME ASSESSMENT; PAPULE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SKIN COLOR; TELANGIECTASIA; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIMETHYL SULFOXIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ROSACEA; SEVERITY OF ILLNESS INDEX; SILYMARIN; SKIN; SULFONES; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 38949159704     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2008.00355.x     Document Type: Article

References (16)

1. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41; quiz 342-4.
2. Dahl MV. Rosacea subtypes: A treatment algorithm. Cutis 2004; 74 (3 Suppl.): 21-7, 32-4.
3. Oztas MO, Balk M, Ogus E, Bozkurt M, Ogus IH, Ozer N. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188-92.
4. Murphy G. Ultraviolet light and rosacea. Cutis 2004; 74 (3 Suppl.): 13-6, 32-4.
5. Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol 2005; 19: 646-7.
6. Rigopoulos D, Kalogeromitros D, Gregoriou S et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol 2005; 19: 564-8.
7. Berardesca E, Borroni G. Instrumental evaluation of cutaneous hydration. Clin Dermatol 1995; 13: 323-7.
8. Pierard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998; 10: 1-11.
9. Schmutz JL. Rosacea and UV light. Ann Dermatol Venereol 2006; 133: 467-9.
10. Jones D. Reactive oxygen species and rosacea. Cutis 2004; 74 (3 Suppl.): 17-20, 32-4.
11. Yale SH, Vasudeva S, Mazza JJ et al. Disorders of flushing. Compr Ther 2005; 31: 59-71.
12. Jiang C, Agarwal R, Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem Biophys Res Comm 2000; 276: 371-8.
13. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: Implications for angioprevention and antiangiogenic therapy. Oncogene 2005; 24: 1188-202.
14. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003; 12: 933-9.
15. Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004; 24: 353-63.
16. Magnuson BA, Appleton J, Ryan B, Matulka RA. Oral developmental toxicity study of methylsulfonylmethane in rats. Food Chem Toxicol 2007; 45: 977-84.